Rami Mosrie is an associate in the corporate department in Ropes & Gray’s New York office. Rami represents clients on a broad range of corporate and commercial matters, including commercial contracts, mergers and acquisitions, corporate governance, compliance, and securities. Rami has experience advising clients in the technology, life sciences, consumer products, retail, real estate, and pharmaceutical industries, among others.
Prior to joining Ropes & Gray, Rami was an associate in the corporate group at another leading global law firm in New York. While in law school, Rami served as managing editor and communications chair of the Emory International Law Review.
- Represented Pfizer in its $11.6 billion acquisition of Biohaven Pharmaceuticals.
- Represented HP in its $3.3 billion acquisition of Poly.
- Represented Acceleron Pharma in its $11.5 billion sale to Merck.
- Represented a leading global pharmaceutical company in its acquisition of a medical device company.
- Represented Total System Services in its $21.5 billion merger of equals with Global Payments.*
- Represented Xerox Holdings Corporation in the restructuring of its relationship with FUJIFILM Holdings Corporation, including the $2.3 billion sale of Xerox’s stake in Fuji Xerox.*
- Represented United Parcel Service in its $800 million sale of UPS Freight to TFI International. *
- Negotiated a multi-million-dollar strategic partnership amongst two Fortune 500 companies.*
- Represented Xerox Holdings Corporation in a $35 billion unsolicited offer and proxy contest.*
- Represented General Motors in its $4 billion senior unsecured note offering.*
*Experience prior to joining Ropes & Gray
- JD, with honors, Emory University School of Law, 2018; Managing Editor and Communications Chair, Emory International Law Review; Transactional Law Certificate Recipient
- BS (Finance), summa cum laude, University of Central Florida, 2015
Admissions / Qualifications
- New York, 2019
- LMG Life Sciences Americas Awards “Impact Deal of the Year” for advising Pfizer in its $11.6 billion acquisition of Biohaven Pharmaceuticals